Research ArticleOriginal Research

From Bench to Clinic: Accessing Promising Investigational Medications for Patients with HIV Infection in an Urban Family Health Center

John Weiser, Alice Welch and Neil Calman
The Journal of the American Board of Family Medicine September 2010, 23 (5) 566-570; DOI: https://doi.org/10.3122/jabfm.2010.05.090257

Article Figures & Data

Tables

  • Table 1.

    Baseline Characteristics of Participants

    Baseline Variablen (%)
    Sex
        Women23 (92)
        Men2 (8)
    Race/ethnicity
        Non-Hispanic black9 (36)
        Non-Hispanic white10 (40)
        Hispanic6 (24)
    Insurance type
        Medicaid8 (32)
        Medicare3 (12)
        Commercial13 (52)
        ADAP1 (4)
    Referral source
        Internal11 (44)
        Academic center8 (32)
        Private practice6 (24)
    Baseline labs (median [range])
        CD4 count (cells/mm2)114 (6–524)
        Viral load (copies/mL)54, 581 (<50–670, 000)
    Referral source
        Internal11 (44)
        Academic center8 (32)
        Private practice6 (24)
    Eligibility criteria
        Resistance24 (96)
        Intolerance1 (4)
    Study medications
        ETV1 (4)
        RAL4 (16)
        ETV/RAL19 (76)
        ETV/RAL/MVC1 (4)

    • ADAP, New York State AIDS Drug Assistance Program; ETV, etravirine; RAL, raltegravir; MVC, maraviroc.

  • Table 2.

    Median CD4 Lymphocyte Count and Viral Load Levels: Baseline, On Treatment, and Median Change

    BaselineOn TreatmentMedian ChangeP*
    CD4 lymphocyte count (cells/mm3)114 (6 to 524)229 (29 to 515)95 (−57 to 333)<.0001
    HIV-1 RNA (copies/mL)43, 177 (<50 to 670, 000)<50 (<50 to >100, 000)−49, 173 (59, 291 to −669, 951).0002

    • * Wilcoxon signed rank test.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section